Top Seattle, WA Biotech Companies (31)
Don't see your company?
Create a company profile
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with our customers, we are driven to make healthcare better.
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+ consultants around the world through our Nextcontinent partnership, we work where you do to deliver the change you seek.
Parse Biosciences is a Seattle-based startup providing researchers access to the most scalable single cell sequencing platform available. With technology founded on the principles of SPLiT-seq, published in Science in 2018, Parse Biosciences' mission is to accelerate progress in scientific research as well as human health. Single-cell sequencing has already enabled groundbreaking discoveries that have led to new understandings in cancer treatment, tissue repair, stem cell therapy, the immune system and much more. At Parse Biosciences we provide researchers with the ability to perform single cell sequencing with unprecedented scale and ease.
Outpace Bio is a venture-backed biotechnology company building a platform to create next-generation smart cell therapies. Our world-class scientific team is developing cell therapies that intervene in complex biology in ways that small molecules and biologics cannot. Our rich platform combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. We create mechanism-driven solutions tailor-made to dramatically improve efficacy and safety. Our partnership business model will accelerate the clinical validation of our platform and the development of truly curative therapies. We value teamwork, creativity, integrity, rigor, and passion for science. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
We are a biotech company with a fierce commitment to the patients and communities we serve. Period. We are a company dedicated to recoding science so we can help rewrite the stories of those living with severe genetic diseases and cancer. We live by our non-negotiables: authenticity, courage, humility, caring and transparency. Every day, in every interaction.
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. Located in Seattle, Washington, InBios offers superior quality products which are accurate, easy to use and cost effective. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit http://www.inbios.com.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Halo-Bio RNAi Therapeutics Inc. is an early stage company.
Adaptive Symbiotic Technologies is a dynamic agricultural biotech company based in Seattle, Washington, U.S.A. We focus on the research and production of symbiotic plant microbes as agricultural crop treatments for farmers. This symbiotic relationship between crops and microbes allows plants to tolerate abiotic stress and increase uptake of soil nutrients naturally. This dynamic relationship is a cooperative approach to making plants healthier and more adaptable to increasing climate changes around the globe. We are continually searching for new microbial symbionts and organic plant treatments to increase agricultural sustainability and farmers' profitability. Our intent is to make this technology available to small and large-scale farmers in first world and developing nations to help increase crop yields and decrease human hardship.
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions. Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
BRIOTECH HOCl is a globally-focused disruptive supplier of pure HOCl and deployable remotely controlled factories for community empowerment. We produce a pure HOCl from saltwater re-synthesis that has been shown to be a virtual bio mimic of the body’s own defense system (phagocytosis in white blood cells). HOCl stops replication of virtually all pathogens without creation of resistance & persistence mechanisms (superbugs). BrioHOCl solution was tested by NIH on the world’s worst pathogens (all prion species) resulting in unprecedented results for inactivation efficacy while maintaining lasting shelf stability and consistent safety profiles. BRIOTECH has never wavered from its focus on what HOCl products can do for the good of mankind, in all aspects of health and wellness, and the company’s intent is to ensure a lasting, beneficial impact on as many people as possible throughout the world by delivering improvements to their daily lives from use of superior, pure, stable, safe and right-priced HOCl products. Applications and compendiums of scientific supporting data will be available in our comprehensive HOCl Codex, “The Handbook of HOCl” summer 2021. BRIOTECH’s unique credentials, strategic management and technical team have raised the company’s status to become an industry leader in the world of HOCl. More information is available at brioglobal.com As a profit-for-purpose company, 5% of its gross sales are dedicated to underserved populations, with a focus on “at risk women, children and indigenous people” through our foundation, BrioEarth
Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the goal of advancing promising laboratory discoveries into patients. Pluristyx has a developed a proprietary footprint-free method to generate induced Pluripotent Stem Cells (iPSCs) from clinically-relevant starting material. Pluristyx iPSCs are manufactured at scale and cryopreserved at high-density in a Ready-to-Differentiate® (RTD®) format that can be immediately thawed for downstream differentiation without the need for additional expansion. Pluristyx also provides the consulting and process development support required to incorporate these RTD®-iPSCs into existing workflows to accelerate product development and clinical translation. In October, 2022 Pluristyx announced a merger with panCELLa. Pluristyx today offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases and cancer, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
Revalesio Corporation, located in Tacoma, WA, is partnering with leaders in biomedical research around the globe to harness the benefits of fluid modification via turbulent Taylor-Couette-Poiseuille (TCP) flow. Revalesio’s patented application of fluid cavitation within a
Oscine Therapeutics is a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
Viome is on a mission to prevent and reverse chronic diseases. Viome is a high-growth biotech startup that applies AI and machine learning to biological data – e.g., microbiome, transcriptome and metabolome data – to provide direct-to-consumer personalized dietary and lifestyle recommendations for healthier living. We are a small, fast-growing, interdisciplinary team of passionate experts in biochemistry, microbiology, medicine, artificial intelligence, and machine learning with a shared mission to make illness optional.
Work Your Passion. Live Your Purpose.
